| Abstrakt: |
Metabolic syndrome refers to risk factors that enhanced the development of cardiovascular disease and diabetes. Resveratrol is a stilbene compound. Various resveratrol derivatives have been isolated and identified from natural product extracts. Those compounds may present in the form of a monomer, dimers, trimers, or even more complex derivatives as the impact of structure modification during biosynthesis. Over the years, resveratrol and its derivatives have been explored on its pharmacological effects. In this paper, we reviewed the potency of several well-characterized resveratrol derivatives isolated from natural product extract for the treatment and prevention of metabolic syndromes. We reveal that resveratrol derivatives can be used for prevention and treatment metabolic syndromes such as obesity, diabetes, hyperuricemia, as well as an inflammatory condition by interfering multiple targets, for example inhibiting several enzymes including xanthine oxidase, lipase, α-glucosidase, DPP-IV, and angiotensin-converting enzyme, activating PPAR-α and PPAR-β/δ, reducing visceral adipose fat, as well as downregulating GLUT9 and URAT1 ion transporter. The potency of those resveratrol derivatives such as gnetin C (isolated from Gnetum gnemon seed) and mulberroside A (isolated from Morus alba) seem superior as compared with trans-resveratrol as its parental compound in vitro and exhibited positive effect in an animal model. Hence, we suggest natural product extract containing resveratrol derivatives may provide promising prospects as an alternative medicine for treatment and prevention of metabolic syndrome. [ABSTRACT FROM AUTHOR] |
